Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes

An Outtier(KU Leuven), Séverine Vermeire(KU Leuven), Liese Gijbels(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), João Sabino(KU Leuven), Maja Noman(KU Leuven)

Inflammatory Bowel Diseases

November 9, 2022

10.1093/ibd/izac227

Cited by 9

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

|Nature Genetics|2008|2.6k

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis

|Gut|2013|1.9k

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

|Journal of Crohn s and Colitis|2018|1.8k

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

|New England Journal of Medicine|2016|1.8k

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

|Journal of Crohn s and Colitis|2019|1.4k